24 June 2016 - PHARMAC is seeking feedback on a proposal involving enoxaparin sodium and plerixafor, resulting from a provisional agreement with Sanofi.

The proposal includes price reductions for enoxaparin sodium and the listing of plerixafor for use in DHB hospitals.

In summary, this proposal would result in:

• Price reductions for all funded strengths of enoxaparin sodium (Clexane), the first being effective 1 September 2016 and the second on 1 September 2017.
• Listing of plerixafor (Mozobil), a treatment used during mobilisation for autologous stem cell transplants, in Part II of Section H of the Pharmaceutical Schedule from 1 September 2016.

For more details, go to: http://www.pharmac.govt.nz/news/consultation-2016-06-24-enoxaparin-plerixafor/